The impact of homocysteine, B\textsubscript{12}, and D vitamins levels on functional neurocognitive performance in HIV-positive subjects

Katia Falasca\textsuperscript{1*}, Marta Di Nicola\textsuperscript{2}, Giuseppe Di Martino\textsuperscript{3}, Claudio Ucciferri\textsuperscript{1,4}, Francesca Vignale\textsuperscript{1}, Alessandro Occhionero\textsuperscript{1} and Jacopo Vecchiet\textsuperscript{1}

Abstract

Background: The correlation among high levels of total homocysteine, low levels of B\textsubscript{12} vitamin, and neurocognitive impairment in HIV negative patients has been the main research topic in some of the latest reviews. The aim of this study was to examine if the alteration of homocysteine, B\textsubscript{12} vitamin, and D vitamins plasma levels was present in HIV-positive, and their relationship with cognitive function.

Methods: 57 HIV infected were enrolled and underwent the serum measurement of homocysteine, B\textsubscript{12}, and D vitamins. The neurocognitive evaluation investigated 5 cognitive domains, through a neuropsychological battery test

Results: Homocysteine was found to be elevated in 70.2% of cases, B\textsubscript{12} vitamin mean levels were low in 8 participants (14.0%), and 8 patients had D hypovitaminosis (14.0%). Abnormal homocysteine levels were associated with worse performance of verbal fluency ($p=0.003$) and worse executive function (Stroop E test $p=0.040$). The 25-OH D hypovitaminosis was associated with worse performances in executive functions in three different tests: Stroop E ($p=0.049$), Trail B ($p=0.035$), and Wais Digit Span ($p=0.042$). Pathological levels of B\textsubscript{12} Vitamin were also associated to worse performances in executive functions (Trail B Test and Wais Digit Span respectively $p=0.002$ and 0.029) and with a lower speed in psychomotor processing (Peg Board Test on dominant hand, $p=0.014$).

Conclusions: In this study serum homocysteine, B\textsubscript{12}, and D vitamin levels are associated with neurocognitive performances; in fact low performance neurocognitive was correlated with hyperhomocysteine and low B\textsubscript{12} vitamin, and D vitamin levels. Evidence of the alteration of these parameters could facilitate the early identification of a neurocognitive impairment.

Keywords: Sulphur amino acids, Vitamin, Neuropsychological examination, Cognitive impairment

There are no conflict of interest. No financial support was given for the study.

background

The prevalence of HIV-associated neurocognitive disorders (HAND), especially asymptomatic and milder forms, remains high even in patients undergoing a stable and successful combination antiretroviral therapy (cART) [1]. The presence of risk factors for HAND should heighten clinical suspicion for the disorder; these include host factors, HIV disease factors, and comorbidities. Host factors include genetic predisposition and metabolic disorders. More important are the associations of HAND or ANI (Asymptomatic Neurocognitive Impairment) with metabolic disorders, aging, and vascular disease [2].

The metabolism of homocysteine depends on folate, B\textsubscript{12}, and B\textsubscript{6} vitamins. Therefore elevated levels of homocysteine are a marker of B\textsubscript{12} and/or folate deficiency [3]. In a longitudinal HIV-negative population based study of older adults without dementia, higher levels of B\textsubscript{12} vitamin and lower levels of homocysteine were associated with a decreased rate of loss brain volume over 6 years [4]. Rates of brain atrophy were significantly correlated with levels of homocysteine in the Study on Cognition and Prognosis...
in the Elderly [5], and lower levels of B12 vitamin were associated with an increased rate of brain volume loss in the Oxford Project to Investigate Memory and Aging study [6]. B12 vitamin and folate have a strong connection with the metabolism of homocysteine, a sulphur-containing non-essential amino acid. High levels of homocysteine and low levels of B12 vitamin and folate are common in the elderly and correlate with several conditions, such as cardiovascular and cerebrovascular diseases [7]. These biochemical alterations could even have an impact on brain structure through several physiopathological pathways [8].

In older HIV-negative adults, higher blood levels of homocysteine have also been associated with brain atrophy [9] and with increase of white matter lesions volume over time [10], although more studies are needed to confirm these data [11].

D vitamin deficiency has been associated with a pro-inflammatory state that induces blood vessels injury but is also connected to other vascular risk factors [12], and perhaps these vascular disorders cause neurocognitive disorders.

However, to our best knowledge, very few studies have examined the association of homocysteine with brain damage, evaluated by neurocognitive deficit, in subjects with HIV infection [13].

The aim of this study was to assess the prevalence of hyperhomocisteinemia in HIV+ patients and to examine the relationship between homocysteine, B12, and D vitamins levels and cognitive function evaluated through the analysis of five cognitive domains, which may represent useful peripheral indicators of brain activity.

Methods

Study design

Analytical transversal study including fifty-seven (57) caucasian participants with HIV infection who were under continuous ART, followed at the Clinic of the Infectious Diseases, Department of Medicine and Science of Ageing, “G. d’Annunzio” University (Chieti-Pescara, Italy) was performed.

Patients were clinically stable and virologically suppressed and had a CD4+ cell count > 300 cells/mL during the six months before the beginning of the observational period. The patients had no opportunistic infections during this time and no antiretroviral therapy changes in the year before the study started.

After that laboratory and neurocognitive tests were performed, the patients received a D vitamin supplementation if they showed D hypovitaminosis, in accordance with the current guidelines.

During their baseline visit, blood sample was taken for routine laboratory analysis. Moreover, a clinical assessment was performed. Patients were advised to report any adverse events or changes in their condition throughout the study and to continue their usual diet and lifestyle. Excluding criteria were: (a) steroids, growth hormone, testosterone or any anabolic agent use in the previous six months; (b) drug and alcohol abuse; (c) acute infection in the previous three months; (d) kidney disease and reduced glomerular filtration rate; (e) acute hepatic disease and (f) previous diagnosis of HAND.

This study was conducted in accordance with the guidelines proposed in the Declaration of Helsinki. All participants gave informed consent for the study and the study was approved by the Ethics Committee at the University “G. d’Annunzio” Chieti-Pescara (Ethics Committee Project No.3 the 06/02/2012) and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Overnight fasting venous blood samples were collected for immunological analyses during the intervention period for analysis.

Neuropsychological examination

All patients underwent a comprehensive neurocognitive test evaluating memory, attention and working memory, executive functions, speed of psychomotor processing, and language. [14].

The following tests were used to examine the above-mentioned neurocognitive skills. For memory: Immediate and Delayed recall of Rey’s words, Delayed recall of Rey’s figure; speed of psychomotor processing was evaluated through Grooved Pegboard Test for both dominant and non dominant hand, attention and working memory through Digit span Forward, Spatial span Forward, Double Barrage, executive functions though Stroop test, Trail Making Test B, Drawings, and WAIS Digit Symbol and language through Letter fluency. The Zung Depression scale in order to assess a mood disorder and the Instrumental Activities of Daily Living (IADL) Scale were also administered.

A trained medical doctor (KF) administered and scored all tests, adjusting them for age, gender, and education on the basis of data available for the general Italian population.

A mild cognitive impairment was diagnosed with a score lower than the normative cut-off in more than three tests [15].

Biochemical analyses

We collected fasting venous blood samples from the antecubital vein of patients at their first examination, determining complete blood count, creatinine, plasma levels of triglycerides, total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, glucose, and albumin. Laboratory tests were performed at our hospital in the Division of Clinical Pathology.
Serum D vitamin concentrations were measured in EDTA by radioimmunoassay, DiaSorin, Balton -UK – according to the manufacturer’s instructions. B12 plasma vitamin and serum folate were quantified using an electrochemiluminescence immunoassay on a cobas e analyzer (Roche, Penzberg, Germany). Total homocysteine was measured in plasma samples by stable isotope dilution liquid chromatography tandem mass spectrometry using a Quattro micro instrument (Waters Corporation, Milford, MA, USA), as described by Magera et al. [16]

Virologic and immunologic markers
Plasma viral load (HIV-RNA) was determined using the “Amplicor” method (Roche Molecular Diagnostics, Milan, Italy) with a sensitivity of 40 HIV RNA copies/mL of plasma. CD4 + – and CD8 + –T cell counts were obtained by flow cytometry of lymphocyte subpopulations.

Statistical methods
According to the main endpoint of the study, the sample size determination was based on the prevalence of hyperhomocysteinemia in HIV population based on previously observed data and published results [17]. Assuming a prevalence of 70%, with a precision of 10% and a 95% confidence interval, at least 57 patients were needed. Quantitative variables were summarized as mean and standard deviation (SD) or median and interquartile range (IQR) according to their distribution; qualitative variables were summarized as frequency and percentage. A Shapiro-Wilk’s test was performed to evaluate the departures from normality distribution for each variable. Mann-Whitney U-test was performed to evaluate differences of Homocysteine, B12, and D vitamins between patients with and without pathological value of cognitive test. Logistic regression models were performed to estimate the relationship between Homocysteine, B12, and D vitamins and ANI diagnosis. The results of models were expressed as odds ratio (OR) and relative 95% confidence interval (95% CI). The number of type I errors, was controlled applying the Gavrilov-Benjamini-Sarkar procedure to bound the false discovery rate (FDR) ≤0.05. All statistical tests were evaluated at an alpha level of 0.05. Statistical analysis were performed using IBM® SPSS Statistics v 20.0 software (SPSS Inc., Chicago, Illinois, USA).

Results
Study population
A total of 60 Italian participants (50 males, 83.3%), with 51.0 ± 9.8 years of age and 10.8 ± 3.1 years of mean education were enrolled. Three participants were not included into analyses due to incomplete serum sampling. All patients were in cART without therapeutic changes for more than 12 months. All patients were on cART according to currently accepted guidelines. Viral load was persistently undetectable and the median CD4+ cell count was 646 cells/μl (IQR 523–964 cells/μl). The mean serum concentrations of main metabolic values, such as glucidic and lipidic parameters, showed no meaningful discrepancies. Markers of liver and kidney functions did not show any substantial change compared to a range of normality. Furthermore, the mean BMI (Body mass index) was 25.7 ± 3.6 kg/m² (Table 1).

Homocysteine, B12, and D Vitamins
The mean value of homocysteine was 15.1 ± 6.3 μmol/l and high levels of homocysteine (plasma level ≥12 μmol/l) [18] were found in 40 participants (70.2% of cases). The mean level of B12 vitamin was 378.5 ± 151.8 ng/ml with levels under 200 ng/L in 8 participants (14.0%); vitamin D Table 1
| Patient’s characteristics (n = 57) |
|-----------------------------|
| Variable                   | Value            |
| Age (ys)                   | 51.0 ± 9.8       |
| Gender, n(%)               |                 |
| Male                       | 50 (87.7)        |
| Female                     | 7 (12.3)         |
| BMI (Kg/m²)                | 25.7 ± 3.6       |
| Level of instruction (ys)  | 10.8 ± 3.1       |
| History of HIV infection (ys) | 11.1 ± 7.5    |
| Risk factors, n(%)         |                 |
| MSM                        | 22 (38.6)        |
| Ex-IDU                     | 11 (19.1)        |
| Heterosexual               | 24 (42.1)        |
| Therapy, n(%)              |                 |
| NRTI                       | 53 (93.0)        |
| NNRTI                      | 20 (35.1)        |
| IP                         | 20 (35.1)        |
| INSTIs                     | 20 (35.1)        |
| HCV, n(%)                  | 9 (15.8)         |
| HBV, n(%)                  | 6 (10.5)         |
| Glycaemia (mg/dl)          | 98.8 ± 48.8      |
| Total cholesterol (mg/dl)  | 198.2 ± 44.2     |
| HDL cholesterol (mg/dl)    | 51.8 ± 16.9      |
| LDL cholesterol (mg/dl)    | 113.4 ± 40.0     |
| Triglycerides (mg/dl)      | 164.8 ± 99.0     |
| Creatinine (mg/dl)         | 1.0 ± 0.9        |
| Albumin (g/dl)             | 4.6 ± 1.0        |
| 25-OH D Vitamin (ng/ml)    | 26.8 ± 9.3       |
| Homocysteine (μmol/l)      | 15.1 ± 6.3       |
| B12 Vitamin (ng/ml)        | 378.5 ± 151.8    |
| Folate (ng/ml)             | 98 ± 13.7        |

MSM men sex with men; IDU injection drug users; NRTI nucleoside reverse transcriptase inhibitor; NNRTI non-nucleoside reverse transcriptase inhibitor; IP Protease Inhibitors; INSTIs Integrase strand transfer inhibitors
mean value was $26.8 \pm 9.3$ ng/ml. No patients had an alteration in all of the three parameters. The folate levels were normal in all patients, with a mean value of $9.8 \pm 13.7$ ng/ml.

Neurocognitive examination
All cognitive impaired patients showed an ANI profile type, without significant interference in the everyday life (IADL $\geq 7$). By analyzing the proportion of impairments, which scored below the normal cut-off, for each single task, median values did not significantly differ with the normal parameter, but 42 patients (73.7%) showed three or more pathologic tests (57.9%), 24 patients had more than three pathologic tests (43.6%) and 16 patients had more than 4 pathologic tests (29.1%). The overall tests assessment showed that 21.1% of patients had pathological result in the battery exploring Memory tests and 19.3% of them showed problems in long time-memory; 66.7% of patients showed a pathological test of attention and working memory, 57.9% was pathologic on executive functions, 31.6% had low points on speed of psychomotor processing. For 12 patients (21.1%) there was a significant pathologic result in Zung Depression scores. Raw scores for each task and comparison cut-off are illustrated in Table 2.

Clinical variables and neurocognitive functions
Abnormal homocysteine levels were associated with worsened performance in verbal fluency ($p = 0.003$) and worse executive functions (Stroop E test $p = 0.040$). 25-OH D hypovitaminosis was associated with worse performances in executive functions in three different test: Stroop E ($p = 0.049$), Trail B ($p = 0.035$) and Wais Digit Span ($p = 0.042$). Pathological levels of B12 vitamin were also associated with worse performances in executive functions (Trail B Test and Wais Digit Span respectively $p = 0.002$ and 0.029) and with lower speed of psychomotor processing (Peg Board Test on dominant hand, $p = 0.014$) (Table 3). No significant relations were found among pharmacological therapy, HBV/HCV co-infections and vitamins levels. The group that received an ANI diagnosis (over 3 pathologic neurocognitive tests) showed lower levels of 25-OH D vitamin compared with the patients that had less than 3 pathologic tests ($p = 0.022$) (Fig. 1). No difference in homocysteine levels and B12 vitamin levels were found

### Table 2 Cognitive test performances

| Test Category          | Test Name                               | Median (IQR) | Normality Range/Cut-off | Pathologic Test, n (%) |
|------------------------|-----------------------------------------|--------------|-------------------------|------------------------|
| MEMORY                 | Rey BT                                  | 39.0 (34.0–44.0) | > 28.53               | 12 (21.1)*             |
|                        | Rey LT                                  | 8.0 (6.0–10.0)   | > 4.69                | 11 (19.3)              |
| ATTENTION AND WORKING MEMORY | Verbal Span forward               | 5.0 (4.0–6.0)     | 5.00–9.00            | 18 (31.6)              |
|                        | Spatial Span forward                  | 3.0 (3.0–5.0)     | 5.00–9.00            | 37 (64.9)              |
|                        | Double barrage                         | 1.0 (1.0–1.0)     | > 0.92               | 6 (10.5)               |
| EXECUTIVE FUNCTIONS    | Stroop E                                | 1.0 (0–2.0)       | < 4.24               | 8 (14.0)               |
|                        | Stroop T                                | 19.0 (14.0–28.0)  | < 36.91              | 10 (17.5)              |
|                        | Trail making test B - T                | 149.0 (112.0–220.0) | 111.29*-248.89*   | 10 (17.5)              |
|                        | Trail making test B - E                | 1.0 (0–2.0)       | < 0.21–2.39          | 6 (10.5)               |
|                        | Drawings                               | 5.0 (3.0–6.0)     | 3.85–6.15            | 16 (28.1)              |
|                        | Wais Digit span                        | 33.0 (23.0–45.0)  | > 6.00               | 14 (24.6)              |
| LANGUAGE               | Verbal fluency test                    | 33.0 (27.0–41.0)  | > 17.35              | 5 (8.8)*               |
| SPEED OF PSYCHOMOTOR PROCESSING | Pegboard dom          | 72.0 (62.0–82.0)  | 55.94–74.32         | 18 (31.6)              |
|                        | Pegboard non dom                      | 75.0 (68.0–85.0)  | 59.68–80.30         | 10 (17.5)              |
| DEPRESSION             | Zung depression score                  | 38.0 (31.0–46.0)  | < 50.00              | 12 (21.1)*             |
| DAILY LIFE ACTIVITY    | IADL                                    | 8.0 (8.0–8.0)     | < 7.00               | –                      |

*Patients with at least one pathologic test in the relative domain. IQR Interquartile Range
Table 3  Differences in cognitive test among patients with or without pathologic values of Homocysteine, 25-OH D Vitamin and B12 Vitamin

| Cognitive test       | Homocysteine | 25-OH D Vitamin | B12 Vitamin |
|----------------------|--------------|-----------------|-------------|
|                      | Non-Pathologic | Pathologic (n = 40) | Non-Pathologic (n = 49) | Pathologic (n = 8) | Non-Pathologic (n = 49) | Pathologic (n = 8) |
| Rey word BT          | 38.0 (31.0–43.3) | 39.0 (32.5–44.3) | 39.5 (34.0–44.3) | 31.0 (22.5–38.8) | 39.9 (33.5–45.5) | 39.0 (23.0–40.5) |
| Rey word LT          | 7.0 (4.0–10.0) | 8.0 (6.0–9.8) | 7.0 (5.0–9.8) | 5.5 (4.0–7.8) | 7.5 (5.0–10.0) | 7.0 (4.0–9.0) |
| Verbal Span          | 5.0 (3.0–6.0) | 5.0 (4.0–6.0) | 5.0 (4.0–6.0) | 5.0 (5.0–5.8) | 5.0 (4.0–6.0) | 5.0 (2.5–5.5) |
| Forward              | 4.0 (3.0–5.0) | 3.5 (3.0–5.0) | 4.0 (3.0–5.0) | 4.0 (3.0–5.0) | 4.0 (3.0–5.0) | 5.0 (2.5–5.5) |
| Stroop E Test        | 2.0 (1.8–3.5) | 1.0 (0–2.0) | 1.0 (0–2.0) | 3.0 (2.0–10.8) | 1.5 (0–2.0) | 4.0 (0.5–9.5) |
| Stroop T Test        | 20.0 (13.5–38.5) | 17.0 (12.3–36.0) | 17.0 (13.3–26.0) | 24.0 (14.5–39.5) | 16.0 (12.8–26.3) | 26.0 (17.0–50.0) |
| Trail B T            | 154.0 (107.0–236.3) | 137.5 (92.3–213.0) | 131.5 (96.0–195.3) | 281.0 (152.3–403.8) | 133.5 (93.8–198.8) | 338.0 (186.5–387.5) |
| Trail B E            | 1.0 (0–1.8) | 0 (0–2.0) | 0 (0–2.0) | 1.5 (0.3–3.5) | 0 (0–1.3) | 2.0 (0–4.0) |
| Drawings             | 5.5 (4.0–6.0) | 4.5 (3.0–6.0) | 4.5 (3.0–6.0) | 2.0 (0.5–5.5) | 5.0 (4.0–6.0) | 2.0 (0.5–4.0) |
| Verbal Fluency       | 24.0 (17.0–33.3) | 36.5 (29.3–48.0) | 34.5 (29.0–41.5) | 23.0 (16.0–42.0) | 34.5 (27–47.3) | 24.0 (17.0–39.5) |
| Wais Digit Span      | 29.5 (19.3–49.3) | 33.5 (21.5–44.0) | 32.0 (23.0–44.0) | 12.5 (6.8–29.5) | 33.5 (22.5–46.3) | 9.0 (6.5–32.0) |
| Double Barrage       | 12.0 (9.0–12.3) | 11.0 (10.0–12.8) | 11.5 (10.3–12.0) | 10.5 (9.3–12.5) | 11.0 (10.0–12.0) | 13.0 (9.5–13.0) |
| Pegboard Dominant    | 76.0 (66.5–79.8) | 73.5 (64.5–87.8) | 75.0 (67.0–80.0) | 97.5 (71.3–145.5) | 72.0 (64.8–80.0) | 100.0 (81.0–131.0) |
| Pegboard Non-Dominant| 75.5 (69.0–86.8) | 77.0 (68.3–90.5) | 77.5 (69.3–85.8) | 96.5 (78.5–146.8) | 75.0 (67.5–87.5) | 83.0 (76.5–131.5) |
| Zung Depression Score| 43.5 (33.5–53.0) | 34.5 (29.3–48.0) | 36.5 (29.3–48.0) | 45.5 (41.3–56.5) | 38.0 (30.8–46.0) | 44.0 (31.0–53.0) |

*p-value < 0.05

Discussion
In this study, a population with high rates of altered metabolic parameters was examined, such as: homocysteine, vitamin B<sub>12</sub>, and vitamin D; more than half of the patients showed high levels of homocysteine and B<sub>12</sub>.
Our findings show that serum homocysteine, B_{12} vitamin and D vitamin levels are correlated to neurocognitive performances. Evidence of the alteration of these parameters could facilitate the early identification of a neurocognitive impairment. There are some evidences that early detection and management of these laboratory parameters may contribute both to primary and to secondary prevention for neurologic involution.

It could be appropriate to assess in large multicenter intervention studies if the reduction of homocysteine levels and the increase in D and B_{12} vitamins levels are linked to significant neurocognitive performances improvement.

**Abbreviations**
cART: Combination antiretroviral therapy; HAND: HIV-associated neurocognitive disorders; ANI: Asymptomatic Neurocognitive Impairment; IADL: Instrumental Activities of Daily Living; HDL: High-density lipoprotein-cholesterol; LDL: Low-density lipoprotein; SD: Standard deviation;
The authors declare that they have no competing interests.

Competing interests
Not applicable.

Consent for publication
This study was approved by the Ethics Committee at the University of Molise, Chieti-Pescara, Pescara, Italy. 4Department of Medicine and Science of Aging, University "G. d’Annunzio" Chieti-Pescara (60%, 2012–2013) in order to purchase the vitamin D and homocysteine measurement tests. The abovementioned funding body had no direct role in the design of the study, in collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
FK, UC and VJ were responsible for the conception and design of this work. VF, OA and UC contributed in data acquisition. DNM and DMG performed analysis and interpretation of all the data. VI, OA and UC have been involved in drafting the manuscript. VJ gave final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Ethics Committee at the University "G. d’Annunzio" Chieti-Pescara (Ethics Committee Project No.3 the 06/02/2012 and informed consent was waived due to the observational nature of the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Clinic of Infectious Diseases – Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Pescara, Italy. Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio” Chieti-Pescara, Pescara, Italy. 2School of Hygiene and Preventive Medicine - Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Pescara, Italy. 3Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.

Received: 11 April 2018 Accepted: 25 January 2019

Published online: 04 February 2019

References
1. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre S, Marctotte TD, Atkinson JH, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75(23):2087–96.
2. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antirv Med. 2011;19(4):137–42.
3. Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006;580(13):2994–3005.
4. Hooshmand B, Mangialasche F, Kalpouzos G, Solomon A, Kareholt I, Smith AD, Refsum H, Wang R, Muhrmann M, Ertl-Wagner B, et al. Association of vitamin B12, folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal population-based study. JAMA Psychiatry. 2016;73(6):606–13.
5. Narayan SK, Fribank MJ, Saby BK, Stansby G, Hansrani M, O’Brien JT, Ford GA. Elevated plasma homocysteine is associated with increased brain atrophy rates in older subjects with mild hypertension. Dement Geriatr Cogn Disord. 2011;31(5):341–8.
6. Vogiatzoglou A, Refsum H, Johnston C, Smith SM, Bradley KM, de Jager C, Budge MM, Smith AD. Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology. 2008;71(11):826–32.
7. Kallit J, Misra UK. Benefit of vitamin B-12 supplementation in asymptomatic elderly: a matter of endpoints. Am J Clin Nutr. 2015;102(3):529–30.
8. Hooshmand B, Polkowsk T, Kiwipela M, Tarksanen M, Myllräkkäs L, Erikipunti T, Makela M, Oinas M, Paetau A, Scholtes P, et al. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain. 2013;136(9):2707–16.
9. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Outhaj A, Bradley KM, Jacoby R, Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244.
10. Kloppeborg RP, Geerlings MI, Visscher FL, Mali WP, Vermeulen M, van der Graaf Y, Nederkoorn PJ, Group SS. Homocysteine and progression of generalized small-vessel disease: the SMART-MR study. Neurology. 2014;82(9):777–83.
11. Frizba M, Narayan SK, Saby BK, Ford GA, O’Brien JT. Homocysteine is associated with hippocampal and white matter atrophy in older subjects with mild hypertension. Int Psychogeriatr. 2010;22(5):804–11.
12. Park KY, Chung PW, Kim YB, Moon HS, Suh BC, Won YS, Kim JM, Youn YC, Kwon OS. Serum vitamin D status as a predictor of prognosis in patients with acute ischemic stroke. Cerebrovasc Dis. 2015;40(1–2):73–80.
13. Alhgren E, Hagberg L, Fuchs D, Anderson LM, Nilsson S, Zetterberg H, Gilsén M. Association between plasma homocysteine levels and neuronal injury in HIV infection. PLoS One. 2016;11(7):e0158973.
14. Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafaglì M, Silveri MC, Vecchiet J, Cauda R, et al. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients. Infection. 2013;41(6):1103–9.
15. Haddow LJ, Laverick R, Daskalopoulou M, McDinnell J, Lampe FC, Gilson R, Speakman A, Antinori A, Balestra P, Bruun T, et al. Multicenter European prevalence study of neuropsychological impairment and associated factors in HIV positive patients. AIDS Behav. 2017.
16. Magiera MJ, Lacey JM, Cassetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chim. 1999;45(9):1517–22.
17. Deminice R, Silva TC, de Oliveira VH. Elevated homocysteine levels in human immunodeficiency virus-infected patients under antiretroviral therapy: a meta-analysis. World J Virol. 2015;4(2):147–55.
18. Koo K, Still R, Cale S, McDowell I. Standardization (external and internal) of HPLC assay for plasma homocysteine. Clin Chem. 1997;43(9):1653–5.
19. Falasca K, Reale M, Ucciferri C, Di Nicola M, Di Angelo C, Colokonato S, Vecchiet J, Cytokines, hepatic fibrosis, and antiretroviral therapy role in neurocognitive disorders HIV related. AIDS Res Hum Retrovir. 2017;33(3):246–53.
20. Ganguy P, Alon SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:46.
21. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: meta-analysis of eight cohort studies including 8669 participants. Alzheimers Dement. 2011;7(4):412–7.
22. Bongiovanni M, Casana M, Piaceteta M, Tordato F, Ciconni P, Russo U, Ranieri R, Monforte A, Bini T. Predictive factors of hyperhomocysteinaemia in HIV-positive patients. J Acquir Immune Defic Syndr. 2007;44(1):117–9.
23. Remacha AF, Cadafalch J, Sarda P, Barcelo M, Fuster M. Vitamin B-12 metabolism in HIV-infected patients in the age of highly active antiretroviral therapy: role of homocysteine in assessing vitamin B-12 status. Am J Clin Nutr. 2003;77(2):420–4.
24. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM, Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland homocysteine study. Arch Gen Psychiatry. 2003;60(1):73–80.
25. Schneider AL, Lutsey PL, Selvin E, Mosley TH, Sharrett AR, Carson KA, Post WS, Pankow JS, Folsom AR, Gottesman RF, et al. Vitamin D and bone mineral density in older adults: a longitudinal population-based study. JAMA Psychiatry. 2016;73(6):606–13.
27. Falasca K, Ucciferri C, Di Nicola M, Vignale F, Di Biase J, Vecchiet J. Different strategies of 25OH vitamin D supplementation in HIV-positive subjects. Int J STD AIDS. 2014;25(11):785–92.

28. Turetsky A, Goddeau RP Jr, Henninger N. Low serum vitamin D is independently associated with larger lesion volumes after ischemic stroke. J Stroke Cerebrovasc Dis. 2015;24(7):1555–63.